Short Interest in Aptorum Group Limited (NASDAQ:APM) Drops By 23.6%

Aptorum Group Limited (NASDAQ:APM) was the target of a significant decline in short interest in March. As of March 31st, there was short interest totalling 98,500 shares, a decline of 23.6% from the March 15th total of 128,900 shares. Currently, 3.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,330,000 shares, the days-to-cover ratio is currently 0.0 days.

Aptorum Group Price Performance

Aptorum Group stock traded down $0.36 during midday trading on Monday, hitting $7.85. 48,170 shares of the company’s stock were exchanged, compared to its average volume of 2,135,791. Aptorum Group has a 52-week low of $1.35 and a 52-week high of $17.49. The stock has a 50-day moving average price of $5.46 and a two-hundred day moving average price of $3.14.

Hedge Funds Weigh In On Aptorum Group

A hedge fund recently bought a new stake in Aptorum Group stock. Citadel Advisors LLC acquired a new position in Aptorum Group Limited (NASDAQ:APM) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 37,106 shares of the company’s stock, valued at approximately $43,000. Citadel Advisors LLC owned approximately 0.10% of Aptorum Group at the end of the most recent quarter. Hedge funds and other institutional investors own 3.80% of the company’s stock.

Aptorum Group Company Profile

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.